Andrew Lam

Managing Director, Head, Biotech Private Equity at Ally Bridge Group

Speaker

Andrew W. Lam, PharmD is Managing Director, Head of Biotech Private Equity at Ally Bridge Group (ABG), a global healthcare investment firm focused on high-impact life science innovation. Andrew leads ABG’s private investments in therapeutics including CG Oncology, Endeavor BioMedicines, ProfoundBio and RayzeBio. He is a director currently serving on the board of Endeavor BioMedicines and previously of ProfoundBio. Andrew is a clinical pharmacist by training with over two decades of therapeutics-focused professional experience spanning late-stage venture investing, investment banking, equity research and functional roles within industry. He received his Pharm.D. from Long Island University and his MBA from Drexel University.